查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423077

2024-2032 年按治療領域、藥物傳輸、配銷通路和國家分類的學名藥市場報告

Generic Drugs Market Report by Therapy Area, Drug Delivery, Distribution Channel, and Country 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球學名藥市場規模達3,671億美元。展望未來， IMARC Group預計到2032年市場規模將達到6,280億美元，2024-2032年複合年成長率（CAGR）為5.96%。各種慢性疾病的日益普及、製藥業研究相關活動的投資增加以及品牌藥物專利到期的數量增加是推動市場的一些主要因素。

學名藥是指在活性成分、劑型、規格、給藥途徑、品質、安全性和功效方面與品牌藥生物等效的藥物。它們由多種藥物組成，包括布洛芬、二甲雙胍和辛伐他汀。它們是在原廠藥的專利保護到期後生產的。它們已獲得監管機構的批准，並且價格實惠。它們在管理各種健康狀況（如高血壓、糖尿病、感染和心血管疾病）方面發揮著至關重要的作用。它們對於提高負擔能力至關重要，特別是對於沒有全面保險或面臨高額費用的個人而言。

由於品牌藥專利到期數量的增加，對學名藥的需求不斷增加，推動了市場的成長。除此之外，全球醫療保健服務成本的不斷成長也提供了有利的市場前景。此外，全球患有心血管疾病、糖尿病和呼吸系統疾病等各種慢性疾病的老年人口不斷增加，也促進了市場的成長。除此之外，主要市場參與者之間為增加各種學名藥產量而進行的合作數量不斷增加，正在支持市場的成長。此外，製藥業擴大整合技術先進的設備來生產具有特殊配方的各種複雜的學名藥，這也促進了市場的成長。

學名藥市場趨勢/促進因素：

慢性病盛行率上升

目前，由於不健康的生活習慣日益盛行，群眾慢性病盛行率上升。久坐的生活方式和不良飲食（加工食品和快餐的消費增加）是導致糖尿病、心臟病和某些癌症等慢性疾病增加的重要因素。除此之外，過量飲酒和吸煙也導致各種慢性疾病的發生，例如高血壓和心血管併發症。此外，慢性壓力通常是現代快節奏生活方式的副產品，可能會導致一系列健康問題，包括心臟病和精神疾病。然而，增強的篩檢和診斷工具可以更好、更早、更頻繁地檢測慢性病。此外，各種學名藥的消費正在幫助患者治療多種慢性疾病。

製藥業不斷成長的研究相關活動

目前，製藥業為開發新疾病的治療方法和疫苗而進行的研究活動增加。除此之外，隨著世界各地老年人口的增加，對藥物的需求也增加。此外，基因組學、蛋白質組學和生物資訊學等領域的最新突破正在為藥物發現和開發開闢新途徑。在分子層面上操縱基因和蛋白質的能力，以及對分子和基因層面上疾病機制的日益了解，正在為標靶治療的發展鋪平道路。除此之外，製藥公司正在投資生產各種品牌藥物的學名藥，以使患者負擔得起且易於獲得。

越來越多的政府措施提供負擔得起的醫療保健服務

各國管理機構都在大力投資，使醫療服務變得負擔得起，並尋找各種慢性病的治療方法。他們也採取了許多舉措，包括補貼醫療費用、實施降低藥物成本的政策、提供保險以及投資公共衛生設施和計畫。除此之外，各國政府都致力於透過在農村地區建造免費診所來縮小不同收入和社會群體之間的健康差距。這些診所還優先以名目價格提供學名藥和各種其他藥物，並提供免費檢查。

學名藥市場趨勢：

全球老年人口不斷成長，癌症、糖尿病和心血管疾病等慢性疾病的發生率不斷上升，是積極影響市場的關鍵因素之一。此外，飲食模式的改變和個人忙碌的日程安排導致了各種狀況，這反過來又刺激了全球對學名藥的需求。同時，各國政府加強努力降低醫療成本並促進學名藥的生產和使用，也促進了市場的成長。他們還鼓勵主要參與者推出有效的學名藥並提供容易取得的藥物。除此之外，學名藥的低生產成本正在為市場創造積極的前景。此外，製藥公司和醫療商店在全球範圍內的擴張進一步促進了市場成長。此外，領先製造商日益關注推出新產品的合作夥伴策略，正在推動市場成長。此外，對廣泛研發（R＆D）活動的​​投資增加以及藥物配方的技術進步預計將推動市場發展。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球學名藥產業

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場細分：按國家/地區
  • 市場區隔：按治療領域
  • 市場細分：按藥物輸送
  • 市場區隔：按配銷通路
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
    • 研究與開發
    • 製造業
    • 行銷與分銷
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 非專利藥產業的法規
  • 主要市場促進因素與成功因素

第 6 章：主要國家的表現

  • 美國
    • 市場走向
    • 市場預測
  • 中國
    • 市場走向
    • 市場預測
  • 巴西
    • 市場走向
    • 市場預測
  • 德國
    • 市場走向
    • 市場預測
  • 法國
    • 市場走向
    • 市場預測
  • 印度
    • 市場走向
    • 市場預測
  • 英國
    • 市場走向
    • 市場預測
  • 日本
    • 市場走向
    • 市場預測
  • 加拿大
    • 市場走向
    • 市場預測
  • 義大利
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依治療領域

  • 中樞神經系統
    • 市場走向
    • 市場預測
  • 心血管
    • 市場走向
    • 市場預測
  • 皮膚科
    • 市場走向
    • 市場預測
  • 泌尿生殖系統/荷爾蒙
    • 市場走向
    • 市場預測
  • 呼吸系統
    • 市場走向
    • 市場預測
  • 風濕病學
    • 市場走向
    • 市場預測
  • 糖尿病
    • 市場走向
    • 市場預測
  • 腫瘤學
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場細分：依藥物輸送

  • 口服
    • 市場走向
    • 市場預測
  • 注射劑
    • 市場走向
    • 市場預測
  • 皮膚/外用
    • 市場走向
    • 市場預測
  • 吸入器
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按配銷通路

  • 零售藥局
    • 市場走向
    • 市場預測
  • 醫院藥房
    • 市場走向
    • 市場預測

第 10 章：競爭格局

  • 市場結構
  • 市場區隔：按關鍵參與者
  • 主要球員簡介
    • Teva Pharmaceuticals Industries Ltd.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Fresenius SE & Co.
    • Lupin Limited
    • Endo Pharmaceuticals Inc.
    • Aurobindo Pharma Limited
    • Aspen Pharmacare Holdings Limited

第 11 章：學名藥生產流程

  • 產品概述
  • 詳細製程（片劑）
  • 詳細製程（注射）
  • 涉及的各種類型的單元操作
  • 質量平衡和原料要求

第 12 章：專案細節、要求與涉及的成本

  • 土地需求和支出
  • 建設需求及支出
  • 工廠機械
  • 機械圖片
  • 原料需求及支出
  • 包裝要求及費用
  • 交通需求及支出
  • 公用事業要求和支出
  • 人手需求及開支
  • 其他資本投資

第 13 章：貸款與財務援助

第 14 章：專案經濟學

  • 專案資本成本
  • 技術經濟參數
  • 供應鏈各層面的產品定價與利潤
  • 稅金和折舊
  • 收入預測
  • 支出預測
  • 財務分析
  • 利潤分析

圖一覽

表列表

簡介目錄
Product Code: SR112024A549

Abstract

The global generic drugs market size reached US$ 367.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 628.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.96% during 2024-2032. The growing prevalence of various chronic diseases, rising investments in research-related activities in the pharmaceutical industry, and increasing number of patent expirations of brand name drugs are some of the major factors propelling the market.

Generic drugs are medications that are bioequivalent to brand-name drugs in terms of active ingredients, dosage form, strength, route of administration, quality, safety, and efficacy. They consist of a wide range of medications, including ibuprofen, metformin, and simvastatin. They are produced after the patent protection of the brand-name drug expires. They are approved by regulatory authorities and available at affordable prices. They play a vital role in managing various health conditions, such as hypertension, diabetes, infections, and cardiovascular diseases. They are essential in improving affordability, particularly for individuals without comprehensive insurance coverage or facing high expenses.

The increasing demand for generic drugs due to the rising number of patent expirations of brand name drugs is impelling the growth of the market. Besides this, the growing cost of healthcare services around the world is offering a favorable market outlook. In addition, the increasing geriatric population across the globe experiencing various chronic conditions, such as cardiovascular diseases, diabetes, and respiratory disorders, is contributing to the growth of the market. Apart from this, the rising number of collaborations between key market players to increase the production of various generic drugs is supporting the growth of the market. Additionally, the increasing integration of technologically advanced equipment in the pharmaceutical industry to produce various complex generic drugs with specialized formulations is bolstering the growth of the market.

Generic Drugs Market Trends/Drivers:

Rising prevalence of chronic diseases

At present, there is an increase in the prevalence of chronic diseases among the masses due to the rising adoption of unhealthy lifestyle habits. Sedentary lifestyles and poor diet (increased consumption of processed and fast foods) are significant contributors to a rise of chronic ailments like diabetes, heart disease, and certain cancers. Apart from this, the excessive consumption of alcohol and tobacco is propelling the occurrence of various chronic disorders, such as hypertension and cardiovascular complications. In addition, chronic stress, often a byproduct of the modern, fast-paced lifestyle, can contribute to a host of health problems, including heart disease and mental illness. However, enhanced screening and diagnostic tools are leading to better, earlier, and more frequent detection of chronic conditions. Furthermore, the consumption of various generic drugs is helping patients to treat a wide array of chronic diseases.

Growing research-related activities in the pharmaceutical industry

At present, there is an increase in research activities in the pharmaceutical industry to develop treatments and vaccines for emerging diseases. Besides this, the demand for medications is increasing as the geriatric population is rising around the world. Moreover, recent breakthroughs in areas, such as genomics, proteomics, and bioinformatics, are opening new avenues for drug discovery and development. The ability to manipulate genes and proteins at a molecular level, and the increasing understanding of disease mechanisms at the molecular and genetic levels, are paving the way for the development of targeted therapies. Apart from this, pharmaceutical companies are investing in manufacturing various generic versions of branded drugs to make them affordable and easily accessible for patients.

Increasing number of government initiatives to provide affordable healthcare services

Governing agencies of various countries are heavily investing in making healthcare services affordable and finding treatments for various chronic illnesses. They are also taking numerous initiatives, including subsidizing healthcare costs, implementing policies to reduce the cost of drugs, providing insurance coverage, and investing in public health facilities and programs. Apart from this, governing authorities of various countries are focusing on reducing health disparities among different income and social groups by constructing free clinics in various rural areas. These clinics are also prioritizing generic drugs and various other medications for nominal prices, along with free checkups.

Generic Drugs Market Trends:

The growing global geriatric population and the rising occurrence of chronic medical disorders, such as cancer, diabetes, and cardiovascular diseases, represent one of the key factors positively influencing the market. In addition, changing dietary patterns and hectic schedules of individuals are leading to various conditions, which, in turn, is catalyzing the demand for generic drugs worldwide. Along with this, increasing efforts by governments of various countries to reduce healthcare costs and promote the manufacturing and uptake of generics are contributing to the market growth. They are also encouraging key players to introduce effective generic drugs and provide easy availability. Apart from this, the low production cost of generic medicines is creating a positive outlook for the market. Additionally, the expansion of the pharma companies and medical stores across the globe is further augmenting the market growth. Furthermore, the rising focus of leading manufacturers on partnership strategies to launch new products is propelling the market growth. Moreover, increasing investments in extensive research and development (R&D) activities and technological advancements in medicine formulation are anticipated to drive the market.

Generic Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global generic drugs market report, along with forecasts at the global and country levels from 2024-2032. Our report has categorized the market based on therapy area, drug delivery, and distribution channel.

Breakup by Therapy Area:

Central Nervous System

Cardiovascular

Dermatology

Genitourinary/Hormonal

Respiratory

Rheumatology

Diabetes

Oncology

Others

Central nervous system dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes central nervous system, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. According to the report, central nervous system represented the largest segment.

Generic drugs play a significant role in the treatment of various central nervous system (CNS) disorders. They offer several benefits, including affordability, accessibility, and comparable efficacy to their brand-name counterparts. They comprise serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, and escitalopram, that are commonly prescribed for these conditions. They also consist of antiepileptic drugs, including levetiracetam, lamotrigine, and topiramate, which are commonly prescribed and have proven efficacy in controlling seizures. They are used to treat Parkinson's disease and attention deficit hyperactivity disorder (ADHD).

Generic drugs are employed for curing cardiovascular complications, such as hypertension or hypertension, coronary artery diseases, heart failure, and arrhythmias. They consist of diuretics, aldosterone antagonists, digoxin, beta-blockers, and calcium channel blockers.

Breakup by Drug Delivery:

Oral

Injectables

Dermal/Topical

Inhalers

Oral holds the largest share in the market

A detailed breakup and analysis of the market based on the drug delivery have also been provided in the report. This includes oral, injectables, dermal/topical, and inhalers. According to the report, oral accounted for the largest market share as they are generally easy to administer and can be self-administered by the patient. They can be taken at home or on the go without the need for medical supervision or assistance. Besides this, oral drugs can be obtained from pharmacies, hospitals, or prescribed by healthcare providers, making it convenient for patients to obtain and take their medications. They can be taken in a non-invasive manner by eliminating the need for needles, injections, or invasive procedures, which can be uncomfortable or cause anxiety for some individuals. They can get absorbed through the digestive system, allowing for efficient delivery into the bloodstream. Furthermore, oral medications offer a higher level of patient compliance as they are easy to consume regularly.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Retail pharmacies account for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes retail pharmacies and hospital pharmacies. According to the report, retail pharmacies accounted for the largest market share.

Retail pharmacies, also known as community pharmacies or outpatient pharmacies, are establishments wherein prescription medications, over the counter (OTC) drugs, and other healthcare products are dispensed and sold directly to consumers. These pharmacies are commonly found in retail settings, such as drugstore chains, supermarkets, or independent pharmacies. They play a crucial role in providing accessible and convenient pharmaceutical services to the public. They present a wide variety of medications, including pain relievers, cough and cold medicines, allergy medications, and more. Besides this, they often stock various health and wellness products, such as supplements, vitamins, personal care items, first aid supplies, and medical devices like blood pressure monitors and glucose meters.

Breakup by Country:

United States

China

Brazil

Germany

France

India

United Kingdom

Japan

Canada

Italy

Others

The United States exhibits a clear dominance, accounting for the largest generic drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include the United States, China, Brazil, Germany, France, India, the United Kingdom, Japan, Canada, Italy, and others.

The United States held the biggest market share since the region has an advanced medical infrastructure and efficient regulatory support. Besides this, the increasing number of insurance companies and healthcare providers encouraging patients to consume generic drugs is propelling the growth of the market. Apart from this, increasing availability of generic drugs at affordable prices are bolstering the growth of the market. Moreover, the growing occurrence of various chronic diseases among the masses is influencing the market positively.

China is estimated to expand further in this domain due to the increasing investments in developing novel drugs and promoting the use of generic drugs. Besides this, the rising construction of hospitals, nursing homes, and clinics is propelling the growth of the market in the country.

Competitive Landscape:

Key market players are investing in research activities to develop a pipeline of generic drugs. They are also focusing on identifying opportunities to introduce generic versions of brand-name drugs as patents expire. Top companies are forming strategic partnerships or engaging in acquisitions to strengthen their market position and expand their capabilities. They are also collaborating with other generic drug manufacturers, contract research organizations (CROs), or acquiring smaller companies to achieve access to new markets or technologies. Leading companies are expanding their geographic reach by entering new market positions and establishing a presence in emerging economies. They are also focusing on the development of complex generic drugs, such as extended-release formulations, transdermal patches, inhalers, and injectables.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Teva Pharmaceuticals Industries Ltd.

Mylan N.V.

Novartis AG

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Fresenius SE & Co.

Lupin Limited

Endo Pharmaceuticals Inc.

Aurobindo Pharma Limited

Aspen Pharmacare Holdings Limited

Recent Developments:

In May 2023, Teva Pharmaceuticals Industries Ltd. announced that it will present data demonstrating UZEDY (risperidone) extended-release injectable suspension for subcutaneous use.

In June 2022, Pfizer Inc. declared the presentation of a New Drug Application (NDA) for approval of PAXLOVID™ (tablets and ritonavir tablets) to the U.S. FDA for patients who are at severe risk of illness from COVID-19.

In July 2020, Mylan N.V. announced the commercial launch of Remdesivir under the brand name DESREM in India to fulfill the urgent demand amid the coronavirus pandemic.

Key Questions Answered in This Report

  • 1. What was the size of the global generic drugs market in 2023?
  • 2. What is the expected growth rate of the global generic drugs market during 2024-2032?
  • 3. What are the key factors driving the global generic drugs market?
  • 4. What has been the impact of COVID-19 on the global generic drugs market?
  • 5. What is the breakup of the global generic drugs market based on the therapy area?
  • 6. What is the breakup of the global generic drugs market based on the drug delivery?
  • 7. What is the breakup of the global generic drugs market based on the distribution channel?
  • 8. What are the key regions in the global generic drugs market?
  • 9. Who are the key players/companies in the global generic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drugs Industry

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Country
  • 5.5 Market Breakup by Therapy Area
  • 5.6 Market Breakup by Drug Delivery
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Research and Development
    • 5.10.2 Manufacturing
    • 5.10.3 Marketing and Distribution
  • 5.11 Porter's Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes
  • 5.12 Regulations in the Generic Industry
  • 5.13 Key Market Drivers and Success Factors

6 Performance of Key Countries

  • 6.1 United States
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 China
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Brazil
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Germany
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 France
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 India
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 United Kingdom
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Japan
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Canada
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast
  • 6.10 Italy
    • 6.10.1 Market Trends
    • 6.10.2 Market Forecast
  • 6.11 Others
    • 6.11.1 Market Trends
    • 6.11.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Central Nervous System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dermatology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Genitourinary/Hormonal
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Respiratory
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Rheumatology
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Diabetes
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Oncology
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Others
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast

8 Market Breakup by Drug Delivery

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Dermal/Topical
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Inhalers
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Hospital Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Key Player Profiles
    • 10.3.1 Teva Pharmaceuticals Industries Ltd.
    • 10.3.2 Mylan N.V.
    • 10.3.3 Novartis AG
    • 10.3.4 Pfizer Inc.
    • 10.3.5 Sun Pharmaceutical Industries Ltd.
    • 10.3.6 Fresenius SE & Co.
    • 10.3.7 Lupin Limited
    • 10.3.8 Endo Pharmaceuticals Inc.
    • 10.3.9 Aurobindo Pharma Limited
    • 10.3.10 Aspen Pharmacare Holdings Limited

11 Generic Drugs Manufacturing Process

  • 11.1 Product Overview
  • 11.2 Detailed Process Flow (Tablets)
  • 11.3 Detailed Process Flow (Injectable)
  • 11.4 Various Types of Unit Operations Involved
  • 11.5 Mass Balance and Raw Material Requirements

12 Project Details, Requirements and Costs Involved

  • 12.1 Land Requirements and Expenditures
  • 12.2 Construction Requirements and Expenditures
  • 12.3 Plant Machinery
  • 12.4 Machinery Pictures
  • 12.5 Raw Material Requirements and Expenditures
  • 12.6 Packaging Requirements and Expenditures
  • 12.7 Transportation Requirements and Expenditures
  • 12.8 Utility Requirements and Expenditures
  • 12.9 Manpower Requirements and Expenditures
  • 12.10 Other Capital Investments

13 Loans and Financial Assistance

14 Project Economics

  • 14.1 Capital Cost of the Project
  • 14.2 Techno-Economic Parameters
  • 14.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 14.4 Taxation and Depreciation
  • 14.5 Income Projections
  • 14.6 Expenditure Projections
  • 14.7 Financial Analysis
  • 14.8 Profit Analysis

List of Figure

  • Figure 1: Global: Generic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Generic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Generic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Generic Drugs Market: Breakup by Country (in %), 2023
  • Figure 5: Global: Generic Drugs Market: Breakup by Therapy Area (in %), 2023
  • Figure 6: Global: Generic Drugs Market: Breakup by Drug Delivery (in %), 2023
  • Figure 7: Global: Generic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Generic Drugs Industry: SWOT Analysis
  • Figure 9: Global: Generic Drugs Industry: Value Chain Analysis
  • Figure 10: Global: Generic Drugs Industry: Porter's Five Forces Analysis
  • Figure 11: USA: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 12: USA: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 13: China: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 14: China: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 15: Brazil: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 16: Brazil: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 17: Germany: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 18: Germany: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 19: France: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 20: France: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 21: India: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 22: India: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 23: United Kingdom: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 24: United Kingdom: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 25: Japan: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 26: Japan: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 27: Canada: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 28: Canada: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 29: Italy: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 30: Italy: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 31: Others: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 32: Others: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 33: Global: Generic Drugs Market: Oral (in Million US$), 2018 & 2023
  • Figure 34: Global: Generic Drugs Market Forecast: Oral (in Million US$), 2024-2032
  • Figure 35: Global: Generic Drugs Market: Injectables (in Million US$), 2018 & 2023
  • Figure 36: Global: Generic Drugs Market Forecast: Injectables (in Million US$), 2024-2032
  • Figure 37: Global: Generic Drugs Market: Dermal/Topical (in Million US$), 2018 & 2023
  • Figure 38: Global: Generic Drugs Market Forecast: Dermal/Topical (in Million US$), 2024-2032
  • Figure 39: Global: Generic Drugs Market: Inhalers (in Million US$), 2018 & 2023
  • Figure 40: Global: Generic Drugs Market Forecast: Inhalers (in Million US$), 2024-2032
  • Figure 41: Global: Generic Drugs Market: Central Nervous System (in Million US$), 2018 & 2023
  • Figure 42: Global: Generic Drugs Market Forecast: Central Nervous System (in Million US$), 2024-2032
  • Figure 43: Global: Generic Drugs Market: Cardiovascular (in Million US$), 2018 & 2023
  • Figure 44: Global: Generic Drugs Market Forecast: Cardiovascular (in Million US$), 2024-2032
  • Figure 45: Global: Generic Drugs Market: Dermatology (in Million US$), 2018 & 2023
  • Figure 46: Global: Generic Drugs Market Forecast: Dermatology (in Million US$), 2024-2032
  • Figure 47: Global: Generic Drugs Market: Genitourinary/Hormonal (in Million US$), 2018 & 2023
  • Figure 48: Global: Generic Drugs Market Forecast: Genitourinary/Hormonal (in Million US$), 2024-2032
  • Figure 49: Global: Generic Drugs Market: Respiratory (in Million US$), 2018 & 2023
  • Figure 50: Global: Generic Drugs Market Forecast: Respiratory (in Million US$), 2024-2032
  • Figure 51: Global: Generic Drugs Market: Rheumatology (in Million US$), 2018 & 2023
  • Figure 52: Global: Generic Drugs Market Forecast: Rheumatology (in Million US$), 2024-2032
  • Figure 53: Global: Generic Drugs Market: Diabetes (in Million US$), 2018 & 2023
  • Figure 54: Global: Generic Drugs Market Forecast: Diabetes (in Million US$), 2024-2032
  • Figure 55: Global: Generic Drugs Market: Oncology (in Million US$), 2018 & 2023
  • Figure 56: Global: Generic Drugs Market Forecast: Oncology (in Million US$), 2024-2032
  • Figure 57: Global: Generic Drugs Market: Other Therapy Areas (in Million US$), 2018 & 2023
  • Figure 58: Global: Generic Drugs Market Forecast: Other Therapy Areas (in Million US$), 2024-2032
  • Figure 59: Global: Generic Drugs Market: Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 60: Global: Generic Drugs Market Forecast: Retail Pharmacies (in Million US$), 2024-2032
  • Figure 61: Global: Generic Drugs Market: Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 62: Global: Generic Drugs Market Forecast: Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 63: Generic Drugs Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 64: Generic Drugs Manufacturing: Production Cost Breakup (in %)
  • Figure 65: Generic Drugs Manufacturing: Detailed Process Flow
  • Figure 66: Generic Drugs Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 67: Generic Drugs Manufacturing: Proposed Plant Layout
  • Figure 68: Generic Drugs Manufacturing Plant: Breakup of Capital Costs (in %)

List of Table

  • Table 1: Global: Generic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Generic Drugs Market Forecast: Breakup by Country (in Million US$), 2024-2032
  • Table 3: Global: Generic Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Generic Drugs Market Forecast: Breakup by Drug Delivery (in Million US$), 2024-2032
  • Table 5: Global: Generic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Generic Drugs Market: Competitive Structure
  • Table 7: Generic Drugs Market: Key Players
  • Table 8: Generic Drugs Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 9: Generic Drugs Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 10: Generic Drugs Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 11: Generic Drugs Manufacturing Plant: Raw Material Requirements
  • Table 12: Generic Drugs Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 13: Generic Drugs Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 14: Details of Financial Assistance Offered by Financial Institutions
  • Table 15: Generic Drugs Manufacturing Plant: Capital Costs (in US$)
  • Table 16: Generic Drugs Manufacturing Plant: Techno-Economic Parameters
  • Table 17: Generic Drugs Manufacturing Plant: Taxation and Depreciation (in US$)
  • Table 18: Generic Drugs Manufacturing Plant: Income Projections (in US$)
  • Table 19: Generic Drugs Manufacturing Plant: Expenditure Projections (in US$)
  • Table 20: Generic Drugs Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in US$)
  • Table 21: Generic Drugs Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in US$)
  • Table 22: Generic Drugs Manufacturing Plant: Profit and Loss Account (in US$)